China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025

In 2025, China’s National Medical Products Administration (NMPA), through its Center for Medical Device Evaluation (CMDE), released 12 batches of announcements admitting 104 products into the Special Review Procedure for Innovative Medical Devices. More than a procedural disclosure, the results indicate areas of regulatory-recognized technological and clinical focus.

For international medical device manufacturers active in, or preparing to enter, the China market, this list indicates key areas of innovation, where competition is intensifying, and how approval expectations are evolving.

Continue reading for an in-depth breakdown of the 2025 innovation review outcomes, or refer to Cisema’s China Medical Device Approval Tracker for Imported Class II & III Devices for a structured overview of recent NMPA approval trends and imported device registrations.

Understanding the Special Review Procedure for Innovative Medical Devices

Understanding the implications of the 2025 results requires context around the regulatory role of the Special Review Procedure itself.

Often referred to as the “Green Channel,” the Special Review Procedure for Innovative Medical Devices is designed to accelerate registration for products that demonstrate both technical originality and clear clinical value. Admission into this pathway enables prioritized communication with evaluation authorities and access to targeted technical guidance during the registration process, supporting more efficient regulatory communication and potentially accelerating registration progress.

To qualify in 2025, admitted products were required to meet several core regulatory criteria:

• Intellectual property ownership: the applicant must legally own the product’s core intellectual property rights within China
• Technical originality: the primary working principle or mechanism of action must either be domestically novel in principle, or demonstrate fundamental improvements in performance or safety
• Clinical significance: the product must demonstrate fundamental improvements in performance or safety with meaningful clinical application value

Eight Product Categories Defining China’s Innovation Priorities

The 104 admitted products span eight major categories, offering a consolidated view of where regulatory focus and clinical demand intersect. Across categories, two themes are consistent:

1. Increasing technical complexity
2. Heightened expectations for measurable clinical impact.

Vascular Intervention Devices (22 Items)

Vascular intervention represents one of the most concentrated innovation areas in the 2025 results, reflecting sustained regulatory focus on acute and complex cardiovascular conditions.

Key innovation directions include:

• Complex structural designs for challenging anatomical indications
• Advanced and biodegradable materials
• Drug-loading and targeted delivery technologies
• Improved efficiency in mechanical thrombectomy

Representative products include intracranial thrombectomy stents, biodegradable occluders, branched aortic stents, and particle-loadable portal vein stents.

For international manufacturers, this concentration signals faster-moving competition and a higher bar for defensible differentiation, particularly in neurovascular and peripheral segments where regulatory differentiation increasingly hinges on proprietary materials, device architecture, and clinical performance data.

Energy Ablation and Radiotherapy Equipment (14 Items)

Energy-based therapies and radiotherapy systems show strong regulatory momentum, with innovation progressing along multiple technical routes in parallel.

Products admitted in 2025 include:

• Cardiac pulsed field ablation systems
• Proton therapy systems
• Boron Neutron Capture Therapy platforms

This diversity reflects regulatory openness to next-generation treatment modalities. Competitive advantage in this space is increasingly shaped by technology generation, system integration, and clinical validation rather than scale or cost efficiency.

Implantable and Active Implantable Devices (22 Items)

Implantable devices continue to evolve toward intelligent, responsive, and minimally invasive systems. Admitted products illustrate several converging trends:

• Wireless and miniaturized device architectures
• Closed-loop therapeutic systems
• Integration of sensing, control, and delivery functions
• Application of tissue engineering technologies

Examples include wireless brain–computer interfaces, closed-loop insulin delivery systems, leadless pacemakers, and cartilage regeneration scaffolds. For international companies, these developments reinforce the importance of aligning hardware innovation with software, algorithms, and long-term clinical evidence strategies.

Smart Diagnosis, Treatment, and Medical Software (10 Items)

Digital and software-driven technologies are increasingly represented within the Special Review Procedure, reflecting clearer regulatory expectations for AI-enabled medical devices.

Products admitted include:

• AI-assisted breast ultrasound diagnostic software
• Spinal surgery navigation systems
• Coronary intervention control platforms

Regulators appear to favor solutions that are deeply embedded within clinical workflows and supported by robust validation, rather than standalone analytical tools.

Biomaterials and Tissue Repair Products (12 Items)

Innovation in biomaterials remains foundational across multiple therapeutic areas and continues to receive regulatory recognition.

Key material directions include:

• Biodegradable metals such as magnesium and zinc alloys
• Bio-derived materials
• Materials designed to induce tissue regeneration

Examples admitted in 2025 include biodegradable bone screws, acellular conjunctival matrices, and collagen meniscus implants. Regulatory evaluation increasingly emphasizes translational readiness and clinical applicability rather than purely material novelty.

Gene Testing and Diagnostic Reagents (9 Items)

Admitted products focus on:

• Early disease screening
• Companion diagnostics
• Infectious disease identification
• Prognostic and monitoring applications

Representative examples include newborn genetic disease screening kits, tumor minimal residual disease detection assays, and tuberculosis drug-resistance gene tests. Diagnostic products that directly inform treatment selection or disease management continue to receive stronger regulatory attention.

Imaging and Large-Scale Medical Equipment (5 Items)

Although fewer in number, high-end imaging systems remain strategically important within the innovation framework.

The inclusion of multiple advanced X-ray computed tomography systems reflects sustained regulatory interest in performance-driven imaging innovation. Evaluation criteria increasingly emphasize system-level improvements, image quality, and clinical utility rather than incremental hardware updates.

Clinically Urgent and Specialty Devices (3 Items)

A smaller subset of products addresses highly specific clinical or procedural needs, often with immediate safety or workflow benefits.

Examples include continuous needle-free drug delivery systems and disposable electric hemorrhoid staplers. These admissions demonstrate regulatory receptiveness to focused innovations that improve procedural precision or clinical efficiency within defined use scenarios.

Strategic Actions for International Medical Device Companies

The 2025 innovation review results confirm that success in China’s medical device market is increasingly determined by ownership of differentiated core technology and the ability to demonstrate tangible clinical value. As more China-based innovators enter high-end therapeutic and diagnostic segments, foreign medical device manufacturers face heightened expectations to articulate a compelling clinical value proposition supported by a robust evidence plan — even for established products.

Against this backdrop, companies should translate these signals into focused decisions on portfolio prioritization, IP readiness, and evidence planning. The following actions are designed to support that process.

Benchmark Portfolios Against Innovation Review Outcomes

Companies should benchmark their China-facing portfolios against the 104 admitted products to understand not only where direct competition exists, but how regulators are defining innovation within each category. This includes comparing claimed clinical benefits, technical differentiation, and intended clinical use to identify where repositioning, pipeline adjustment, or partnership may be required.

Reassess Intellectual Property Strategies

Because innovation review eligibility depends on how core intellectual property rights are defined, owned, and documented in China, manufacturers should assess whether their current IP position supports both innovation review eligibility and long-term registration objectives.

Core claims, ownership structures, and supporting documentation should be aligned with the product’s intended indications and regulatory pathway, rather than addressed as a downstream filing exercise.

Strengthen Clinical and Academic Evidence Strategies

As regulatory evaluation places greater weight on real clinical impact, companies should prioritize structured engagement with leading clinical and academic institutions. High-quality clinical evidence not only supports innovation review but also strengthens regulatory dialogue and long-term product credibility in an increasingly competitive approval environment.

Final Thoughts: What the 2025 Results Mean for International Companies

China’s 2025 Special Review results mark a clear shift toward medical device innovation grounded in demonstrable clinical value. For international medical device companies, the list signals where strategic preparation matters most.

With more than 20 years of experience supporting medical device companies in China, Cisema helps manufacturers interpret these signals and translate them into practical regulatory and innovation strategies.

Get in touch with Cisema today to move forward with clarity and confidence in China’s evolving medical device regulatory environment.

Further Information

• Learn more about Cisema's China NMPA Medical Device & IVD Registration Services, including regulatory strategy and end-to-end registration support for international manufacturers.
• Explore our China Medical Device Approval Tracker for Imported Class II & III Devices for ongoing visibility into NMPA approval activity and market entry trends.

References

“In 2025, a Total of 104 Medical Devices Enter the Innovation Channel” — China Medical Device Industry Association (Simplified Chinese).